"药价能低，公益投入绝不缩水。"东北制药党委书记王新鹏介绍，7年来，东北制药在辽宁方大集团引 领下，累计投入近3亿元用于产业扶贫、乡村全面振兴及抗疫救灾等社会捐赠。 从守护民生的2元平价药，到通过权威认证的国际化品质；从产业扶贫的精准投资，到乡村全面振兴的 持续发力，东北制药用7年实践将关注民生植入了企业的成长基因。 机制"松绑"带来管理革命 7年前，东北制药担当东北国企改革先锋，加入辽宁方大集团实施混合所有制改革。如今，这家承载着 历史荣光的老牌药企破茧蝶变，在坚守民生保障的同时，正加速向全球医药创新前沿迈进。 两元药片里的民生温度 走进东北制药旗下的东北大药房，"民生小药片专柜"上，企业自己生产的对乙酰氨基酚片2元一板、维 生素C片1.60元/瓶，一直保证供应。"感冒发烧、头疼脑热，就认这个柜台的药，便宜管用还踏实。"一 位沈阳消费者的朴实话语道出了几代人对东北制药的深深信赖。 这份信赖，源于东北制药对产品始终如一的品质坚守。不久前，一场国际公认严苛的"飞行检查"——美 国FDA膳食补充剂现场检查，在东北制药悄然进行。最终，东北制药凭借数年如一日构建的严密质量管 控体系和洁净生产环境，以"零缺陷项"通过检 ...

七年前，东北制药（000597）担当东北国企改革先锋，加入辽宁方大集团（000055）实施混合所有制改 革。七年来，东北制药以破冰之勇成功打破体制壁垒，以弄潮之姿拥抱市场蓝海，书写出高质量发展的 崭新篇章。保供两元民生小药片，跻身细胞治疗最前沿，七载变革，东北制药破茧促蝶变，奋楫正扬 帆。 两元药片里的民生温度 走进东北制药旗下的东北大药房，"民生小药片专柜"上，企业自己生产的对乙酰氨基酚片两元一板、维 生素C片1.60元/瓶，一直保证供应。"感冒发烧、头疼脑热，就认这个柜台的药，便宜管用还踏实。"一 位沈阳消费者的朴实话语道出了几代人对东北制药的深深信赖。 这份信赖，源于东北制药对产品始终如一的品质坚守。不久前，一场国际公认严苛的"飞行检查"——美 国FDA膳食补充剂现场检查，在东北制药悄然进行。最终，东北制药凭借数年如一日构建的严密质量管 控体系和洁净生产环境，以"零缺陷项"通过检查，赢得了国际高端市场的"通行证"。 "药价能低，公益投入绝不缩水。"东北制药党委书记王新鹏介绍，7年来，东北制药在辽宁方大集团引 领下，累计投入近3亿元用于产业扶贫、乡村全面振兴及抗疫救灾等社会捐赠。 从守护民生的2元平价药， ...

核心提示 从守护民生的2元平价药，到通过权威认证的国际化品质；从产业扶贫的精准投资，到乡村全面振兴的 持续发力，东北制药用7年实践将关注民生植入了企业的成长基因。 激活体制 "建议在转化前部屋面至甲醇尾气环保装置检修平台增设固定爬梯，方便员工检修也能消除安全隐 患""建议在包装传输线上增加自动间隔系统，防止多个药盒一同通过，导致承重误判的情况发生"…… 这样一条条看似不起眼的建议，从基层员工的指尖直达决策层案头，经论证后被迅速采纳。 近年来，东北制药持续畅通建言通道，鼓励员工提出合理化建议。仅去年一年，就收到1345条建议，其 中900多条被采纳实施。103分厂厂长杨文锋感慨道："以前碰上堵点、难点，员工是带着'问题'找领 导，现在是带着'方案'找领导。" 这种"我要干"的热情，被体制机制的改革彻底激活。为持续激发员工热情，公司还构建了强有力的激励 机制，近三年累计为员工兑现采购降本、小改小革等各类创新提奖2700余万元。 7年光阴，足以让一粒种子破土而出，茁壮成长；7年变革，也能让一家老牌药企褪去沉疴，重焕生机。 2018年，一根改革的藤蔓将东北制药与辽宁方大集团紧紧缠绕，打破体制壁垒、重组资源、焕发新生。 ...

Core Insights - Liaoning Fangda Group Northeast Pharmaceutical's Q1 2025 report shows a significant increase in R&D investment by 88% year-on-year, indicating a strategic shift towards R&D-driven growth and quality enhancement over mere revenue increase [2][4] Group 1: Quality Improvement and Financial Health - Despite a slight revenue increase of 0.36% in Q1 2025, the company achieved steady improvement in operational quality through refined management and structural optimization [2] - Sales expenses decreased by 20.5% year-on-year, while management expenses also reduced, and R&D expenses rose strategically to 32 million yuan, reflecting precise resource allocation [2] - The company's debt-to-asset ratio fell to 58.82%, a decrease of 2.63 percentage points from the beginning of the year, indicating enhanced financial health and reduced short-term repayment risks [2] Group 2: Innovation and Product Development - Northeast Pharmaceutical is implementing a dual-driven strategy of "innovative drugs + generic drugs," creating a product matrix covering various therapeutic areas including neurology, digestion, endocrinology, oncology, and autoimmune diseases [3] - The company is accelerating its strategic layout in cutting-edge fields, particularly in tumor immunotherapy, with over 10 immune therapy products targeting diseases like pancreatic cancer and colorectal cancer [4] - A notable product in development is a TCR-T cell drug targeting KRASG12D, which is expected to be the first of its kind in China to enter Phase I clinical trials [4] Group 3: Global Market Expansion - The company is leveraging its international presence to enhance its global sales network, with its main products exported to over 100 countries and regions [5] - The global sales strategy has effectively diversified market risks and established sustainable revenue capabilities [5] - Although there may be short-term profit fluctuations due to increased R&D investments, the strategic transformation is showing initial positive results, positioning the company for future growth cycles as innovative therapies are commercialized [5]